Three Peptides From the Atrial Natriuretic Factor Prohormone Amino Terminus Lower Blood Pressure and Produce Diuresis, Natriuresis, and/or Kaliuresis in Humans

BackgroundThree peptides consisting of amino acids 1-30, 31-67, and 79-98 of the 126–amino acid atrial natriuretic factor prohormone (proANF), which have blood pressure-lowering, diuretic, natriuretic, and/or kaliuretic properties in animals, were investigated to determine if they have similar properties in humans. Methods and ResultsThirty-six healthy, normotensive human volunteers (18 men and 18 women, ages 20 to 58 years) were divided into six similar groups based on age, sex, weight, blood pressure, and heart rate. After a 60-minute baseline period, 100 ng of proANFs 1-30, 31-67, 79-98, or ANF/kg body wt per minute was given intravenously for 60 minutes followed by a 3-hour postinfusion data collection period. Each of the atrial natriuretic peptides decreased systolic and diastolic blood pressures (P<.05), with proANF 31-67 causing the largest decrease. Urine flow increased 4- to 12-fold and was still significantly increased (P<.01) for 2 to 3 hours after stopping the respective infusions of proANFs 1-30, 31-67, and 79-98. Atrial natriuretic factor (ANF) increased urine flow 4- to 11-fold but by 2 hours after infusion was significantly increased in only 1 of 6 subjects. Sodium excretion increased 3-to 8-fold, 3- to 6-fold, 0- to 2-fold (NS), and 3- to 11-fold, respectively, with proANFs 1-30, 31-67, 79-98, and ANF. Natriuretic effects of proANFs 1-30 and 31-67 were significantly prolonged (P<.001) compared with ANF. ProANFs 1-30, 31-67, 79-98, and ANF increased potassium excretion 2- to 3-fold, 0-fold, 3- to 4-fold, and 2-fold, respectively. High-performance gel permeation chromatography followed by the respective radioimmunoassays revealed that proANFs 1-30, 31-67, 79-98, and 68-98, as well as ANF circulate as distinct peptides. ConclusionsProANFs 1-30, 31-67, and 79-98, as well as ANF have significant blood pressure-lowering and diuretic properties. ProANFs 1-30 and 31-67 also have natriuretic properties in humans that are significantly (P<.001) prolonged compared with ANF. ProANF 79-98, although not possessing any natriuretic property, is the strongest stimulator of potassium excretion of the four atrial natriuretic peptides.

[1]  F. Friedl,et al.  Atrial natriuretic peptides in the heart and hemolymph of the oyster, Crassostrea virginica: a comparison with vertebrates. , 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.

[2]  B. Brenner,et al.  Atrial natriuretic peptide(31-67) inhibits Na+ transport in rabbit inner medullary collecting duct cells. Role of prostaglandin E2. , 1992, The Journal of clinical investigation.

[3]  B. Ackerman,et al.  Pharmacokinetic Characterization of the Postdistribution Phase of Prohormone Atrial Natriuretic Peptides Amino Acids 1–98, 31–67, and Atrial Natriuretic Factor During and After Rapid Right Ventricular Pacing in Dogs , 1992, Journal of clinical pharmacology.

[4]  D. vesely,et al.  Specific binding site for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. , 1992, Renal physiology and biochemistry.

[5]  D. vesely,et al.  Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distension. , 1991, The American journal of physiology.

[6]  D. Martin,et al.  Three peptides from the ANF prohormone NH(2)-terminus are natriuretic and/or kaliuretic. , 1990, The American journal of physiology.

[7]  V. Catanzarite,et al.  Increase in the plasma levels of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during normal pregnancy. , 1990 .

[8]  D. vesely,et al.  Specific binding sites for prohormone atrial natriuretic peptides 1–30, 31–67 and 99–126 , 1990, Peptides.

[9]  P. Norsk,et al.  Increased Release of the N-Terminal and C-Terminal Portions of the Prohormone of Atrial Natriuretic Factor During Immersion-Induced Central Hypervolemia in Normal Humans 1 , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[10]  S. Bloom,et al.  Increase in plasma concentrations of cardiodilatin (amino terminal pro-atrial natriuretic peptide) in cardiac failure and during recumbency. , 1988, British heart journal.

[11]  J. Sundsfjord,et al.  Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. , 1988, The Journal of clinical endocrinology and metabolism.

[12]  H. Itoh,et al.  Secretion of N‐Terminal Fragment of γ‐Human Atrial Natriuretic Polypeptide , 1988 .

[13]  D. vesely,et al.  Two new hormones: prohormone atrial natriuretic peptides 1-30 and 31-67 circulate in man. , 1988, Biochemical and biophysical research communications.

[14]  H. J. Kramer,et al.  Atrial natriuretic hormones. , 1988, General pharmacology.

[15]  D. vesely,et al.  Circadian rhythm of prohormone atrial natriuretic peptides 1-30, 31-67 and 99-126 in man. , 1988, Chronobiology international.

[16]  D. A. Baeyens,et al.  Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta. , 1987, Biochemical and biophysical research communications.

[17]  D. vesely,et al.  Human prepro atrial natriuretic factors 26-55, 56-92, and 104-123 increase renal guanylate cyclase activity. , 1987, Biochemical and biophysical research communications.

[18]  M. Cantin,et al.  Atrial natriuretic factor and urinary kallikrein in the rat: antagonistic factors? , 1984, Canadian journal of physiology and pharmacology.

[19]  J. Laragh,et al.  Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility. , 1984, Hypertension.

[20]  M. Currie,et al.  Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. , 1983, Science.

[21]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.